Numerate CEO and leadership

Brandon Allgood is a Chief Technology Officer at Numerate Inc. He has worked as Research Scientist at Pharmix and Dir:Computational Science at Numerate Inc. Brandon attended Washington University in St LO, WASHINGTON UNIVERSITY, and University of California Santa Cruz.

Guido Lanza is a Chairman at Numerate Inc and VP of Innovation at Valo Health and is based in San Francisco, California. He has worked as CTO at Pharmix; Research Scientist at Genetic Programming, Inc; and Chief Executive Officer at Numerate Inc. Guido works or has worked at Stanford University and works or has worked as Board Member at Pharmix. He studied at University of Manchester between 1998 and 1999, UCLA, and University of California Berkeley between 1994 and 1998.

John Griffin is responsible for Numerate's therapeutic programs and collaborations. He was formerly co-founder and Chief Scientific Officer of Theravance, Inc., a publicly traded biopharmaceutical company. A former Assistant Professor at Stanford University, John is also the author of 39 scientific publications, an inventor of 27 issued patents, and the recipient of numerous awards including an Arthur C. Cope Scholar Award from the American Chemical Society and a Dean's Award for Teaching from Stanford University. He currently serves on the Funding Committee for the Wellcome Trust's Seeding Drug Discovery Initiative. John received a B.S. in Chemistry from Hope College, a Ph.D. in Chemistry from the California Institute of Technology and was a National Science Foundation Postdoctoral Fellow at Harvard Medical School.

Brandon Allgood is a Chief Technology Officer at Numerate Inc. He has worked as Research Scientist at Pharmix and Dir:Computational Science at Numerate Inc. Brandon attended Washington University in St LO, WASHINGTON UNIVERSITY, and University of California Santa Cruz.